- Stocks
- Pharma & Healthcare
- Prevest Denpro
Prevest Denpro share price
NSE: PREVESTPharma & HealthcareMedical Instruments & Supplies
Prevest Denpro at a glance
With a market capitalisation of ₹472 Cr, it ranks 1820th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Instruments & Supplies.
Its return on equity was 16.4% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹19 Cr (+2.7% year on year) and net profit ₹6 Cr (+13.2%), on a consolidated basis. Promoters held 73.60% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹472 CrRank 1820 on NSE
- Price to book
- 3.29×FY26
- EPS (TTM)
- ₹17.07to Q4 FY26
- ROE
- 16.4%FY26
- ROCE
- 21.9%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 28.5%FY26
- Book value / share
- ₹103.97FY26
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Prevest Denpro quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13 Cr | ₹16 Cr | ₹15 Cr | ₹18 Cr | ₹16 Cr | ₹19 Cr | ₹18 Cr | ₹19 Cr |
| Revenue YoY | −0.2% | +23.4% | +9.8% | +13.6% | +18.0% | +14.6% | +23.5% | +2.7% |
| Net profit | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr |
| Net profit YoY | −10.0% | +32.4% | +24.5% | +7.8% | +20.2% | +14.9% | +4.2% | +13.2% |
| Net margin | 27.5% | 29.6% | 30.3% | 27.9% | 28.0% | 29.7% | 25.6% | 30.7% |
| EPS | ₹3.06 | ₹4.01 | ₹3.77 | ₹4.28 | ₹3.67 | ₹4.62 | ₹3.93 | ₹4.85 |
Prevest Denpro financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹56 Cr | ₹63 Cr | — |
| Operating profit | ₹21 Cr | ₹24 Cr | — |
| Net profit | ₹16 Cr | ₹18 Cr | — |
| EPS (₹) | ₹13.00 | ₹15.00 | — |
| Cash from operations | ₹12 Cr | ₹15 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹89 Cr | ₹106 Cr | ₹125 Cr |
Prevest Denpro shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 73.60% | 73.60% | 73.60% | 73.60% | 73.60% | 73.60% |
| Foreign institutions | 0.63% | 0.63% | 0.63% | 0.65% | 0.65% | 0.65% |
| Domestic institutions | 1.28% | 1.22% | 0.75% | 0.77% | 0.77% | 0.79% |
| Non-institutions | 24.49% | 24.54% | 25.01% | 24.98% | 24.98% | 24.96% |
Prevest Denpro vs peers
The listed Pharma & Healthcare companies nearest to Prevest Denpro by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| HSILHemant Surgical | — | — | — | ₹551 Cr | — | — |
| PREVESTPrevest Denpro | — | — | — | ₹472 Cr | — | — |
| HALEOSLABSHALEOS LABS | ₹1,540.00 | +0.59% | +36.5% | ₹466 Cr | 26.9 | — |
| ALBERTDAVDAlbert David | ₹795.00 | −3.90% | −0.6% | ₹454 Cr | — | — |
| ASARFIAsarfi Hospital | — | — | — | ₹446 Cr | — | — |
| JENBURPHJenburkt Pharma | ₹905.20 | −1.63% | — | ₹399 Cr | 11.5 | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
Ask anything about Prevest Denpro
Pivot answers on the live chart with evidence you can check, and tests strategies against PREVEST's own history. Try: “Why has PREVEST moved over the last three months?” · “Backtest a 50-day moving-average crossover on PREVEST over five years” · “Compare PREVEST with HSIL on margins and valuation”
Frequently asked questions about Prevest Denpro
What is the market cap of Prevest Denpro?
Prevest Denpro's market capitalisation is ₹472 Cr (₹472 Cr) at the 19 Oct 2026 close, ranking 1820th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Prevest Denpro?
Return on equity was 16.4% in FY26 and return on capital employed was 21.9% in FY26 (consolidated figures).
Is Prevest Denpro a debt-free company?
Prevest Denpro is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Prevest Denpro's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Prevest Denpro reported revenue of ₹19 Cr, +2.7% year on year, and net profit of ₹6 Cr, +13.2% year on year.
What is the shareholding pattern of Prevest Denpro?
As of 30 Jun 2026: promoters 73.60%, foreign institutions 0.65%, domestic institutions 0.79%, non-institutions 24.96%.
Who are Prevest Denpro's competitors?
The listed Pharma & Healthcare companies closest to Prevest Denpro by market cap are Hemant Surgical, HALEOS LABS, Albert David, Asarfi Hospital, Jenburkt Pharma and Transchem.
Is Prevest Denpro a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Prevest Denpro's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PREVEST against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text